WO1993017034A1 - Derives d'amphothericine b - Google Patents
Derives d'amphothericine b Download PDFInfo
- Publication number
- WO1993017034A1 WO1993017034A1 PCT/GB1993/000306 GB9300306W WO9317034A1 WO 1993017034 A1 WO1993017034 A1 WO 1993017034A1 GB 9300306 W GB9300306 W GB 9300306W WO 9317034 A1 WO9317034 A1 WO 9317034A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- alkyl
- hydrogen
- compound
- group
- Prior art date
Links
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical class O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 title claims description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 39
- 239000001257 hydrogen Substances 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 125000003118 aryl group Chemical group 0.000 claims abstract description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 14
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 14
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 6
- 239000005864 Sulphur Chemical group 0.000 claims abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 239000001301 oxygen Substances 0.000 claims abstract description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 3
- 150000003857 carboxamides Chemical class 0.000 claims description 38
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 29
- 229960003942 amphotericin b Drugs 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 21
- -1 prop-2-enyl Chemical group 0.000 claims description 14
- 206010017533 Fungal infection Diseases 0.000 claims description 13
- 208000031888 Mycoses Diseases 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- 230000000843 anti-fungal effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 125000006242 amine protecting group Chemical group 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 49
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000001819 mass spectrum Methods 0.000 description 18
- 239000011159 matrix material Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 150000003141 primary amines Chemical class 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- NYWPVFGILHJXGJ-QRHLAUAJSA-L copper;(1s,3r,4e,6e,8e,10e,12e,14e,16e,19r,25r,27r,30r,31r,33s,35r,38r)-3-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carb Chemical compound [Cu+2].CC(C)C1=CC(C(C)C)=C(O)C(C([O-])=O)=C1.CC(C)C1=CC(C(C)C)=C(O)C(C([O-])=O)=C1.OC1C(N)C(O)C(C)OC1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(C)[C@@H](O)C(C)C(C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(CC(O)[C@H]2C(O)=O)O[C@H]2C1 NYWPVFGILHJXGJ-QRHLAUAJSA-L 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- RRUNUZOMEZXGPY-UHFFFAOYSA-N 4-ethoxyisoindole-1,3-dione Chemical compound CCOC1=CC=CC2=C1C(=O)NC2=O RRUNUZOMEZXGPY-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 2
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 2
- MDOWENZBDMUQRY-UHFFFAOYSA-N o-[2-[tert-butyl(dimethyl)silyl]oxyethyl]hydroxylamine Chemical compound CC(C)(C)[Si](C)(C)OCCON MDOWENZBDMUQRY-UHFFFAOYSA-N 0.000 description 2
- AQFWNELGMODZGC-UHFFFAOYSA-N o-ethylhydroxylamine Chemical compound CCON AQFWNELGMODZGC-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000004291 polyenes Chemical class 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- YJYAGNPMQVHYAH-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyethanol Chemical compound CC(C)(C)[Si](C)(C)OCCO YJYAGNPMQVHYAH-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 241001537205 Paracoccidioides Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000122969 Streptomyces nodosus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001238303 Turdus fuscater Species 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 201000005889 eumycotic mycetoma Diseases 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- BUTPBERGMJVRBM-UHFFFAOYSA-N methanol;methylsulfinylmethane Chemical compound OC.CS(C)=O BUTPBERGMJVRBM-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- SSUCKKNRCOFUPT-UHFFFAOYSA-N o-[tert-butyl(dimethyl)silyl]hydroxylamine Chemical compound CC(C)(C)[Si](C)(C)ON SSUCKKNRCOFUPT-UHFFFAOYSA-N 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- STMPXDBGVJZCEX-UHFFFAOYSA-N triethylsilyl trifluoromethanesulfonate Chemical compound CC[Si](CC)(CC)OS(=O)(=O)C(F)(F)F STMPXDBGVJZCEX-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- UYUUAUOYLFIRJG-UHFFFAOYSA-N tris(4-methoxyphenyl)phosphane Chemical compound C1=CC(OC)=CC=C1P(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 UYUUAUOYLFIRJG-UHFFFAOYSA-N 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Definitions
- the present invention relates to novel compounds, their preparation and their use in the treatment of fungal infections in animals, including humans.
- the polyene macrolide amphotericin B produced by Streptomyces nodosus, is widely used for the treatment of fungal infections.
- Amphotericin B is the only complex polyene macrolide whose molecular structure and absolute configuration have been firmly established by x-ray crystallographic analysis. Amphotericin B has the formula (A):
- amphotericin B has now been prepared which have novel substituents at the 16-position and which derivatives have been shown to have anti-fungal activity and have potential utility as anti-fungal agents.
- the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:
- R 1 is a group CO.N(R 5 )OR 6 in which R 5 is hydrogen, C 1-6 alkyl, C 3-6 alkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl -C 1-6 alkyl, aryl C 1-6 alkyl, heteroaryl C 1-6 alkyl, aryl, heteroaryl in which any aryl or heteroaryl moiety is optionally substituted,
- s and r together represent 3, 4 or 5 and X represents oxygen, sulphur CH 2 , or NR in which R is hydrogen or C 1-6 alkyl;
- R 6 is a group of formula (ii);
- t is 1 to 6 and R 9 is hydrogen, C 1-6 alkyl or C 3-6 alkenyl;
- R 6 is a group of formula (iii);
- u is 1 to 6 and R 10 and R 11 independently represent hydrogen, or C 1-6 alkyl;
- R 2 is hydroxy or C 1-6 alkoxy;
- R 3 is amino or a derivative thereof;
- R 4 is hydrogen or hydroxy; or R 2 and R 4 together represent a bond.
- an alkyl moiety or group or an alkenyl group preferably has from 1 to 6 carbon atoms, more preferably 1 to 4 carbon atoms and may be straight-chain or branched.
- aryl includes aromatic carbocyclic groups such as phenyl and naphthyl, preferably phenyl.
- heteroaryl includes 5- or 6- membered monocyclic and 9- or 10-membered bicyclic heteroaryl.
- 5- or 6- membered monocyclic and 9- or 10- membered bicyclic heteroaryl preferably contain one or two heteroatoms selected from nitrogen, oxygen and sulphur which in the case of there being more than one heteroatom may be the same or different.
- 9- or 10- membered bicyclic heteroaryl the two rings are fused, preferably with one 5- or 6-membered ring containing a single heteroatom.
- Optional substituents for alkyl, alkenyl, arylC 1-8 alkyl, aryl and heteroaryl groups may be selected from OH, C 1-6 alkyl, C 1-6 alkoxy, carboxy, nitro, halogen, and amino optionally substituted by C 1-6 alkyl, C 1-6 acyl or aryl.
- R 5 in the variable R 1 is preferably hydrogen or methyl.
- R 6 in the variable R 1 is preferably hydrogen, methyl, prop-2-enyl, hydroxyethyl or N-ethylmorpholino.
- R 2 is preferably hydroxy and R 4 is preferably hydrogen.
- R 3 is primary amino
- R 3 is an amine group or derivative thereof
- acyl derivatives bearing a basic substituent such as N-D-lysyl and N-D-ornithyl derivatives, guanidine derivatives, and N-glycosyl derivatives.
- the preparation of further amino group derivatives is described in European Patent Publication 0 010 297 (Schering), European Patent Publication 0 031722 (Dumex) US 4 195 172 and European Patent Publication O 428440.
- pharmaceutically acceptable salt encompasses solvates and hydrates.
- compounds of formula (I) or pharmaceutically acceptable salts thereof form solvates or hydrates, these also form an aspect of the invention.
- the compounds of formula (I) wherein R 3 is hydrogen can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, oxalic, methanesulphonic, aspartic and ascorbic.
- acids such as conventional pharmaceutically acceptable acids, for example hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, oxalic, methanesulphonic, aspartic and ascorbic.
- acids such as conventional pharmaceutically acceptable acids, for example hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, oxalic, methanesulphonic, aspartic and ascorbic.
- the invention also extends to quaternary salts.
- R 2 is hydroxy or C 1-6 alkoxy
- R 3 ' is an amine protecting group and R 4 is hydrogen or hydroxy or R 2 and R 4 together represent a bond and each R 12 is hydrogen or a silyl protecting group; with a compound of formula (III) or, an acid addition salt thereof; in the presence of an amide coupling reagent;
- R 5 is as defined in relation to formula (I)
- R 6 ' is R 6 as defined in relation to formula (I) or a group convertible thereto, and thereafter optionally or as necessary in any appropriate order, converting R 6 ' when other than R 6 to R 6 , converting NHR 3 ' to R 3 , removing the R 12 silyl protecting groups, interconverting R 2 and R 4 , and forming a
- R 6 ' is alkyl
- the reaction between a compound of formula (II) and formula (III) is suitably carried out in an inert solvent such as
- dimethylformamide at ambient temperature in the presence of a buffer such as sodiuim acetate or a base such as pyridine and further in the presence of dicyclohexylcarbodiimide (DCCI) as the amide coupling reagent.
- a buffer such as sodiuim acetate or a base such as pyridine
- DCCI dicyclohexylcarbodiimide
- R 6 ' is other than alkyl
- the reaction between a compound of formula (II) and formula (III) is suitably carried out in an inert solvent such as dimethylformamide in the presence of a base such as N,N-di-isopropylethylamine and in the presence of bromo-tris-pyrrolidinophosphonium-hexafluoro-phosphate as the amide coupling reagent.
- Addition salts of the compound of formula (III) include the hydrochloric and hydrobromic salt thereof.
- the acid addition salt is the hydrochloric salt thereof.
- R 6 ' when a group convertible to R 6 include conventional protecting groups which may be converted to R 6 using conventional deprotection methods such as those described in Greene, T.W. 'Protective groups in Organic Synthesis' New York, Wiley (1981).
- a suitable group convertible to R 6 is hydrogen is a silyl protected group such as i-butyldimethyl silyl which may be converted to a hydrogen by treatment with a salt of a strong acid and a weak base such as pyridinium para-toluene sulphate in a suitable solvent such as a water/THF mixture.
- R 2 is alkoxy and R 4 is hydrogen this reaction converts the alkoxy function to R 2 is hydroxy and this is an example of interconversion of R 2 from alkoxy to hydroxy.
- R 3 ' amine protection groups are chosen such that they are readily removable subsequent to the initial reaction between a compound of formula (II) and a comound of formula (III) or an acid addition salt thereof to provide a compound of formula (I) in which R 3 is hydrogen.
- R 3 ' include trifluoracetyl, 9-fluorenylmethoxycarbonyl, trichloroethoxycarbonyl, 2-methylsulphonylethoxycarbonyl
- R 3 ' is 9-fluorenylmethoxycarbonyl.
- Suitable R 12 silyl protecting groups include trimethylsilyl, triethylsilyl andt-butyldimethylsilyl.
- R 12 is triethylsilyl.
- R 2 hydroxy function can be converted to an alkoxy function using procedures analogous to those outlined in WO/91/0947.
- R 4 Interconversion of R 4 can be carried out according to the procedures outlined in EP-A-0431874 (Beecham Group p.l.c.). Where R 3 in compounds of formula (I) is primary amine the removal of an R 3 ' amine protecting group to give an R 3 primary amine may be carried out under basic conditions.
- An R 3 ' amine protection group such as 9-fluorenylmethoxycarbonyl, may be removed under basic conditions in a solvent such as methanolic dimethyl sulphoxide.
- Suitable bases for amine deprotection include ammonia, dialkylamines such as dimethylamine and diethylamine, trial-kylamines such as triethylamine, cyclic amines and especially cyclic secondary amines such as morpholine, piperazine and more especially piperidine, and diazabicyclic bases such as
- DBN 1,5-diazabicyclo[4.3.0]non-5-ene
- DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
- the deprotection may be carried out using from 1-10 equivalents of base, preferably from 1-2 equivalents, at reduced or elevated temperatures, for example from -30°C to 50°C and preferably from 0°C to room temperature, over a time period ranging from 1 minute to 5 hours and preferably from 30 minutes to 2.5 hours.
- R 12 silyl protecting groups in compounds of formula (II) may be removed using known deprotection methods, for example using a solution of hydrogen fluoride-pyridine in tetrahydrofuran or
- tetrahydrofuran/methanol mixtures at normal or reduced temperature, for example from -10°C to 50°C and preferably from 0°C to room
- Intermediate compounds of formula (II) in which R 4 is hydrogen and R 2 is alkoxy may be prepared from amphotericin B according to the procedures outlined in WO 91/09047 (Beecham Group p.l.c).
- the reaction may be carried out in an inert solvent such as tetrahydrofuran and the alcohol may act either wholly or partially as the solvent.
- the reaction is conveniently carried out in the presence of an H 2 O-scavenger such as molecular sieves and/or under an inert atmosphere.
- R 3 ' amine protection groups may be introduced by standard procedures.
- an R 3 ' trifluoroacetyl amine protection group may be introduced by reaction of the primary amine with ethyl trifluoroacetate in the presence of base such as diisopropylethylamine, in a
- An R 3 ' 9-fiuorenylmethoxycarbonyl amine protection group may be introduced by addition of 9-fluorenylmethyl chloroformate to a solution of the primary amine in methanol-dimethylformamide under anhydrous conditions, in the presence of a base such as potassium carbonate.
- an R 3 ' 9-fluorenylmethoxycarbonyl group maybe introduced by addition of N-(9-fluorenyln ⁇ ethoxycarbonyloxy)sucdnimide to a slurry of the primary amine in rnethanol-diniethylformamide under anhydrous conditions in the presence of a base such as pyridine.
- Free hydroxyl groups may be silylated using standard procedures.
- trifluoromethanesulphonate and triethylsilyl trifluoromethanesulphonate may be carried out in an inert solvent, for example dichloromethane, hexane or diethyl ether, under an inert atmosphere at ambient or reduced temperatures, for example from 0°C to 25°C.
- the reaction is conveniently effected using an excess of the silylating agent in the presence of a base, for example a pyridine derivative such as 2,6-lutidine. Alternatively, when a liquid, the base may replace the solvent.
- the reaction time is dependent on the size of the silyl group, ranging from a few minutes for a trimethylsilyl group to several hours for larger silyl groups.
- the compounds of the formula (I) and their pharmaceutically acceptable salts are anti-fungal agents, potentially useful in combating fungal infections in animals, including humans. For example they are
- Candida albicans e.g. thrush and vaginal candidiasis
- They may also be used in the treatment of systemic fungal infections caused by, for example Candida albicans.
- the invention further provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable diluent or carrier.
- the composition is preferably for human use in tablet, capsule, injectable or cream form.
- pharmaceutically acceptable salts thereof can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- they may be administered orally in the form of a tablet containing such excipients as starch or lactose, or in a capsule or ovule either alone or in admixture with excipients, or in the form of an elixir or suspension containing a flavouring or colouring agent.
- They may be injected parenterally, for example, intravenously,
- the daily dosage level of the antifungal compounds of the formula (I) will be from 0.1 to 1 mg/kg (in divided doses) when administered by either the oral or parenteral route.
- tablets or capsules of the compounds can be expected to contain from 5 mg to 0.5 g of active compound for administration singly or two or more at a time as appropriate.
- the physician in any event will determine the actual dosage which will be most suitable for an individual patient and will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
- the antifungal compounds of formula (I) can be
- a suppository or pessary administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder.
- they can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin; or they can be incorporated, at a concentration between 1 and 10%, into an ointment consisting of a white wax or white soft paraffin base together with such stabilizers and preservatives as maybe required.
- the present invention further provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance.
- a compound for use as an active therapeutic substance is intended for use in the treatment of disorders in animals including humans.
- compounds of formula (I) and their pharmaceutically acceptable salts have anti-fungal activity and are potentially useful in combating fungal infections in animals including humans.
- the present invention further provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of fungal infections.
- the present invention additionally provides a method of treatment of fungal infections in animals, including humans, which comprises administering an effective anti-fungal amount of a compound of formula
- the present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in the treatment of fungal infections in animals, including humans.
- Characteristic signals include:- 1.15 (3H, d, J7.12 Hz), 1.24 (3H, d, J6.59 Hz), 1.35 (3H, d, J6.35 Hz), 1.47 (3H, d, J6.02 Hz), 3.25 (3H, s), 3.90 (3H, s), 4.80 (1H, multiplet), 4.84 (1H, s), 5.47 (1H, multiplet), 5.63 (1H, dd, J14.1 and 9.63 Hz), 6.14 (1H, dd, J14.24 and 6.84 Hz), 6.23-6.61 (12H, complex), 7.30 (2H, t, J7.45 Hz), 7.42 (2H, t, J7.4 Hz), 7.71 (2H, t, J7.08 Hz) and 7.83 (2H, d, J7.51 Hz) ppm.
- amphotericin B 16-(N-methoxy)carboxamide (0.183g, 0.154mmol) in tetrahydrofuran-water (6:1, 7mL) under nitrogen was added pyridinium p-toluenesulphonate (0.292g, 1.16mmol). After stirring in a sealed flask for 1.5 hours triethylamine (0.23mL, 0.167g, 1.65mmol) was added, and the mixture poured into diethyl ether (1L). The precipitate was filtered and washed with diethyl ether (500mL), dry distilled tetrahydrofuran (50ml) then diethyl ether (500mL).
- Characteristic signals include:- 0.95 (3H, d, J7.07 Hz), 1.06 (3H, d, J6.5 Hz), 1.15 (3H, d, J6.3 Hz), 1.21 (3H, d, J4.12 Hz), 3.61 (3H, s), 4.49 (2H, multiplet), 5.03 (1H, multiplet), 5.59 (1H, dd, J14.41 and 9.22 Hz), 5.91 (1H, dd, J14.13 and 6.42 Hz), 6.05-6.45 (12H, complex), 7.35 (2H, t, J7.4 Hz), 7.42 (2H, t, J7.38 Hz), 7.76 (2H, d, J7.09 Hz), and 7.88 (2H, d, J7.5 Hz) ppm.
- amphotericin B (0.29g, 0.25mmol) in dry N,N-dimethyflformamide (2mL) under nitrogen was added successively N,N-diiopropylethylamine (0.15ml, 0.111g, 0.86mmol), O-(tert-butyldimethylsilyl) hydroxylamine (0.038g, 0.25mmol) and bromo-trispyrrolidino-phosphonium hexafluorophosphate [PyBroP] (0.12g, 0.25mmol) and the mixture stirred in a sealed flask for 3 hours.
- Characteristic signals include:- 0.15 (3H, s), 0.16 (3H, s), 0.94 (12H, complex), 1.05 (3H, d, J6.45 Hz), 1.14 (3H, d, J6.45 Hz), 1.18 (3H, d, J6.10 Hz), 2.30 (1H, multiplet), 3.08 (3H, s), 3.60 (1H, multiplet), 4.46 (1H, s), 4.50 (1H, multiplet), 5.04 (1H, multiplet), 5.58 (1H, dd, J14.83 and 9.67 Hz), 5.87 (1H, dd, J14.19 and 7.09 Hz), 6.04-6.45 (12H, complex), 7.34 (2H, t, J7.43 Hz), 7.41 (2H, t, J7.35 Hz), 7.74 (2H, multiplet), and 7.86 (2H, d, 7.60 Hz) ppm.
- Characteristic signals include:- 0.94 (3H, d, J7.07 Hz), 1.06 (3H, d, J6.47 Hz), 1.14 (3H, d, J6.31 Hz), 1.18 (3H, d, J5.43 Hz), 2.30 (1H, multiplet), 3.59 (1H, multiplet), 4.38 (1H, multiplet), 4.48 (1H, s), 5.26 (1H, multiplet), 5.42 (1H, dd, J14 and 10 Hz), 5.98 (1H, dd, J15.05 and 8.70 Hz), 6.12-6.50 (12H, complex), 7.33 (2H, multiplet), 7.41 (2H, t, J7.4 Hz), 7.74 (2H, multiplet) and 7.86 (2H, d, J7.5 Hz) ppm.
- This intermediate was prepared from N-(9-fluorenylmethoxycarbonyl)-13-0-methyl amphotericin B and 0-allyl hydroxylamine in two steps by the methods outlined in descriptions 3 and 4.
- Characteristic signals include:- 0.94 (3H, d, J 7.1Hz), 1.05 (3H, d, J 6.3Hz), 1.13 (3H, d, J 6.4Hz), 1.18 (3H, d, J 5Hz), 3.70 (1H, d, J 2.8Hz), 4.43 (1H, s), 5.43 (1H, dd, J 10, MHz).
- N-(9-fluorenylmethoxycarbonyl) amphotericin B (286 mg, 0.25 mmol) in N,N-dimethylformamide (2.5 ml) was added N,N- diisopropylethylamine (0.225 ml), N-O-dimethyl hydroxylamine
- This material was prepared by the method of description 6.
- Characteristic signals include:- 0.03 (6H, s), 0.85 (9H, s), 0.93 (3H, d, J 7.3Hz), 1.05 (3H, d, J 6.3Hz), 1.13 (3H, d, J 6.4Hz), 1.17 (3H, d, J 5.9Hz), 3.67 (1H, d, J 2.5Hz), 5.44 (1H, dd, J 10.1, 14.3Hz), 5.96 (1H, dd, J 15.0, 8.8Hz).
- N-(9-fluorenylmethoxycarbonyl) amphotericin B 16-[N-(2-t-butyldimethylsilyloxy) ethoxy] carboxamide (0.66 g, 0.5 mmol) in tetrahydrofuran: dimethylformamide (10:1) (33 ml) was added tetra-n-butylammonium fluoride (0.24 g, 0.75 mmol) and the solution stirred at room temperature for 2 hours. The solution was poured into ether (1l) and the solid filtered and washed with water (200 ml), ethyl acetate (500 ml) and ether (500 ml).
- Characteristic signals include:- 0.93 (3H, d, J 7.1Hz), 1.05 (3H, d, J 6.4Hz), 1.13 (3H, d, J 6.4Hz), 1.17 (3H, d, J 5.6Hz), 3.69 (1H, d, J 2.5Hz), 5.43 (1H, dd, J 14.3, 10.1Hz), 5.95 (1H, dd, J 15.1, 9.0Hz).
- N-[2-(4-Morpholino)] ethoxyphthalimide D11
- N-hydroxyphthalimide 2.44 g, 15 mmol
- N-(2-hydroxyethyl) morpholine 1.96 g, 15 mmol
- tri (p-methoxy phenyl) phosphine 5.26 g, 15 mmol
- diisopropylazodicarboxylate 3.33 ml, 17 mmol
- This material was prepared by the mehhod of description 8. ⁇ max (film) 3300 cm -1 .
- This material was prepared by the method of description 6. ⁇ max (MeOH) 405, 382, 363 nm.
- Characteristic signals include:- 0.93 (3H, d, J 7.1Hz), 1.05 (3H, d, J 6.4 Hz), 1.13 (3H, d, J 6.4Hz), 1.18 (3H, d, J 5.9 Hz), 3.68 (1H, d, J 2.7Hz), 4.42 (1H, s), 5.43 (1H, dd, J 14.4, 10.0Hz), 5.96 (1H, dd, J l5.2, 8.9Hz).
- Characteristic signals include;- 0.94 (3H, d, J6.91 Hz), 1.16 (3H, d, J6.15 Hz), 3.63 (3H, s), 4.36 (1H, s), 5.26 (1H, multiplet), 5.42 (1H, dd, J14.36 and 9.96 Hz), 5.98 (1H, dd, J15.36 and 8.85 Hz) and 6.07-6.50 (12H, complex) ppm.
- Characteristic signals include:- 0.94 (3H, d, J6.97 (Hz), 1.06 (3H, d, J6.27 Hz), 1.13 (3H, d, J6.14 Hz), 1.17 (3H, d, J6.01 Hz), 2.31 (1H, multiplet), 4.38 (2H, multiplet), 5.26 (1H, multiplet), 5.43 (1H, dd, J13.71 and 10.26 Hz), 5.99 (1H, dd, J15.13 and 8.66 Hz) and 6.11-6.50 (12H, complex) ppm.
- Characteristic signals include 0.93 (3H, d, J 7.1Hz), 1.05 (3H, d, J 6.4Hz), 1.13 (3H, d, J 6.4Hz), 1.16 (3H, d, J 6.1Hz), 2.39 (1H, d, J 9.5, 3Hz), 2.94 (1H, t, J 9.2Hz), 3.65 (1H, d, J 3Hz), 5.43 (1H, dd, J 14,10Hz).
- Characteristic signals include 0.93 (3H, d, J 7.1Hz), 1.05 (3H, d, J 6.3Hz), 1.13 (3H, d, J 6.3Hz), 1.17 (3H, d, J 6.1Hz), 3.61 (1H, d, J 2.6Hz), 3.72 (3H, s), 5.25 (1H, dd, J 6.3, 2Hz), 5.43 (1H, dd, J 14.4, 10.1Hz), 5.97 (1H, dd, J 15.2, 9Hz).
- the Minimum Inhibitory Concentration was determined by diluting the test compound in a broth medium in a microtitre tray. The organisms, which had been grown previously in a broth medium, were diluted and added to the wells to provide a final inoculum of approximately 10 5 colony-forming units per well. The trays were incubated at 37°C and the turbidity of each well noted at intervals. The MIC was taken as the lowest concentration (in ⁇ g/ml) which prevented significant growth.
- YNB Yeast Nitrogen Base Broth
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un composé de la formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, dans laquelle R1 représente un groupe CO.N(R5)OR6 dans lequel R5 représente hydrogène, alkyle C1-6, alcényle C3-6, cycloalkyle C3-6, C3-6 cycloalkyle -C1-6 alkyle, aryle C1-6 alkyle, hétéoaryle C1-6 alkyle, aryle, hétéroaryle dans lesquels n'importe quelle fraction d'aryle ou d'hétéoaryle est éventuellement substituée; R6 représente hydrogène, alkyle C1-6, alcényle C3-6, cycloalkyle C3-6, C3-6 cycloalkyle -C1-6 alkyle, aryle C1-6 alkyle, hétéroaryle C1-6 alkyle, aryle, hétéroaryle, dans lesquels n'importe quelle fraction d'aryle ou d'hétéroaryle est éventuellement substituée, hydroxyalkyle C2-6, un groupe (CH2)nNR7R8 dans lequel n = 2 à 6; R7 et R8 représentent indépendamment hydrogène ou alkyle C1-6 ou les deux avec l'azote auquel il sont rattachés à partir d'un groupe de la formule (i), dans laquelle s et r réunis représentent 3, 4 ou 5 et X représente oxygène, soufre CH2, ou NR dans lequel R représente hydrogène ou alkyle C1-6; où R6 est un groupe de la formule (ii) dans laquelle t est 1 à 6 et R9 représente hydrogène, alkyle C1-6; ou alcényle C3-6; ou R6 est un groupe de la formule (iii) dans laquelle u est 1 à 6 et R10 et R11 représentent indépendamment hydrogène, ou alkyle C1-6; R2 représente hydroxy ou alcoxy C1-6; R3 représente amino ou un dérivé de celui-ci; et R4 représente hydrogène ou hydroxy; ou R2 et R4 réunis représentent une liaison.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9203476.8 | 1992-02-19 | ||
GB929203476A GB9203476D0 (en) | 1992-02-19 | 1992-02-19 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993017034A1 true WO1993017034A1 (fr) | 1993-09-02 |
Family
ID=10710636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/000306 WO1993017034A1 (fr) | 1992-02-19 | 1993-02-12 | Derives d'amphothericine b |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3461793A (fr) |
GB (1) | GB9203476D0 (fr) |
WO (1) | WO1993017034A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2776927A1 (fr) * | 1998-04-07 | 1999-10-08 | Univ Paris Curie | Compositions pour la vectorisation de molecules |
WO2015190587A1 (fr) * | 2014-06-12 | 2015-12-17 | 塩野義製薬株式会社 | Dérivé de macrolide de polyène |
US9447136B2 (en) | 2012-03-09 | 2016-09-20 | Blirt S.A. | Semisynthetic derivatives of Nystatin A1 |
WO2016168568A1 (fr) | 2015-04-15 | 2016-10-20 | Revolution Medicines, Inc. | Dérivés d'amphotéricine b |
US9745335B2 (en) | 2012-06-15 | 2017-08-29 | Blirt S.A. | N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application |
CN111875653A (zh) * | 2020-08-11 | 2020-11-03 | 深圳市儿童医院 | 一种含二硫键的两性霉素b衍生物及其用途 |
WO2023274313A1 (fr) * | 2021-06-29 | 2023-01-05 | 中国科学院上海药物研究所 | Dérivé semi-synthétique d'amphotéricine b, son procédé de préparation et son utilisation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0375223A2 (fr) * | 1988-12-19 | 1990-06-27 | Beecham Group Plc | Dérivés de l'amphotéricine B, leur préparation et leur utilisation comme médicaments |
EP0431874A1 (fr) * | 1989-12-08 | 1991-06-12 | Beecham Group p.l.c. | Nouveaux composés |
-
1992
- 1992-02-19 GB GB929203476A patent/GB9203476D0/en active Pending
-
1993
- 1993-02-12 AU AU34617/93A patent/AU3461793A/en not_active Abandoned
- 1993-02-12 WO PCT/GB1993/000306 patent/WO1993017034A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0375223A2 (fr) * | 1988-12-19 | 1990-06-27 | Beecham Group Plc | Dérivés de l'amphotéricine B, leur préparation et leur utilisation comme médicaments |
EP0431874A1 (fr) * | 1989-12-08 | 1991-06-12 | Beecham Group p.l.c. | Nouveaux composés |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF ANTIBIOTICS. vol. 35, no. 2, February 1982, TOKYO JP pages 220 - 229 A.JARZEBSKI ET AL. 'Synthesis and Structure-Activity Relationships of Amides of Amphotericin B.' * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051274A1 (fr) * | 1998-04-07 | 1999-10-14 | Universite Pierre Et Marie Curie (Paris Vi) | Derives de macrolide polyenique, utilisation pour la vectorisation de molecules |
FR2776927A1 (fr) * | 1998-04-07 | 1999-10-08 | Univ Paris Curie | Compositions pour la vectorisation de molecules |
US9447136B2 (en) | 2012-03-09 | 2016-09-20 | Blirt S.A. | Semisynthetic derivatives of Nystatin A1 |
US9745335B2 (en) | 2012-06-15 | 2017-08-29 | Blirt S.A. | N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application |
CN106414473B (zh) * | 2014-06-12 | 2020-03-13 | 盐野义制药株式会社 | 多烯大环内酯衍生物 |
WO2015190587A1 (fr) * | 2014-06-12 | 2015-12-17 | 塩野義製薬株式会社 | Dérivé de macrolide de polyène |
EA037093B1 (ru) * | 2014-06-12 | 2021-02-04 | Сионоги Энд Ко., Лтд. | Производное полиенового макролида |
KR20170016957A (ko) | 2014-06-12 | 2017-02-14 | 시오노기 앤드 컴파니, 리미티드 | 폴리엔 마크로라이드 유도체 |
CN106414473A (zh) * | 2014-06-12 | 2017-02-15 | 盐野义制药株式会社 | 多烯大环内酯衍生物 |
JPWO2015190587A1 (ja) * | 2014-06-12 | 2017-04-20 | 塩野義製薬株式会社 | ポリエンマクロライド誘導体 |
US10696707B2 (en) | 2014-06-12 | 2020-06-30 | Shionogi & Co., Ltd. | Polyene macrolide derivative |
US10246478B2 (en) | 2014-06-12 | 2019-04-02 | Shionogi & Co., Ltd. | Polyene macrolide derivative |
JP2018514522A (ja) * | 2015-04-15 | 2018-06-07 | スファンガ セラピューティクス インコーポレイテッドSfunga Therapeutics, Inc. | アムホテリシンbの誘導体 |
US10597420B2 (en) | 2015-04-15 | 2020-03-24 | Sfunga Therapeutics, Inc. | Derivatives of amphotericin B |
US9957290B2 (en) | 2015-04-15 | 2018-05-01 | Sfunga Therapeutics, Inc. | Derivatives of amphotericin B |
US10882883B2 (en) | 2015-04-15 | 2021-01-05 | Sfunga Therapeutics, Inc. | Derivatives of amphotericin B |
WO2016168568A1 (fr) | 2015-04-15 | 2016-10-20 | Revolution Medicines, Inc. | Dérivés d'amphotéricine b |
JP2021075570A (ja) * | 2015-04-15 | 2021-05-20 | スファンガ セラピューティクス インコーポレイテッドSfunga Therapeutics, Inc. | アムホテリシンbの誘導体 |
EP3929203A1 (fr) * | 2015-04-15 | 2021-12-29 | Sfunga Therapeutics, Inc. | Dérivés d'amphotéricine b |
JP2023030103A (ja) * | 2015-04-15 | 2023-03-07 | スファンガ セラピューティクス インコーポレイテッド | アムホテリシンbの誘導体 |
JP7240811B2 (ja) | 2015-04-15 | 2023-03-16 | スファンガ セラピューティクス インコーポレイテッド | アムホテリシンbの誘導体 |
CN111875653A (zh) * | 2020-08-11 | 2020-11-03 | 深圳市儿童医院 | 一种含二硫键的两性霉素b衍生物及其用途 |
WO2023274313A1 (fr) * | 2021-06-29 | 2023-01-05 | 中国科学院上海药物研究所 | Dérivé semi-synthétique d'amphotéricine b, son procédé de préparation et son utilisation |
Also Published As
Publication number | Publication date |
---|---|
AU3461793A (en) | 1993-09-13 |
GB9203476D0 (en) | 1992-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2192427C2 (ru) | Производные эритромицина, обладающие антибактериальной активностью, способ их получения (варианты), фармацевтическая композиция и способ регулирования бактериальной инфекции у млекопитающего | |
US6420538B1 (en) | Aromatic amides, preparation method and application as medicines | |
US9745335B2 (en) | N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application | |
CZ303474B6 (cs) | 6-O-substituovaný ketolidový derivát erythromycinu, zpusob jeho prípravy, jeho použití a farmaceutická kompozice ho obsahující | |
JP2003523938A (ja) | マクロライド系抗感染剤 | |
US4272525A (en) | Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them | |
US5066646A (en) | Amphotericin derivatives | |
US5716939A (en) | Amide derivatives of 16-membered ring antibiotic macrolides | |
WO1993017034A1 (fr) | Derives d'amphothericine b | |
US5100876A (en) | 16-decarboxy-16-hydroxy derivatives of amphotericin b | |
US6284736B1 (en) | Amphotericin derivatives | |
US6664240B2 (en) | Tylosin derivatives having antibacterial activity | |
US5204330A (en) | Antifungal compounds | |
EP1206476B1 (fr) | 9a-azalides a activite antibacterienne | |
US5116960A (en) | Amphotericin b derivatives | |
CA1132542A (fr) | Derives du polyene macrolide antibiotique contenant un sucre amine; procede de preparation et composes pharmaceutiques les contenant | |
CA2191920C (fr) | Derives d'antibiotiques macrolides a anneaux composes de 16 membres de 3-deoxy | |
JP2001515844A (ja) | 3−デスクラジノース6−o−置換エリスロマイシン誘導体 | |
EP1328535B1 (fr) | Macrolides | |
WO1993016090A1 (fr) | Derive d'amphotericine b | |
US6716820B1 (en) | 6-O-substituted bicyclic macrolides | |
WO1993014100A1 (fr) | Derives d'amphotericine b, leur preparation et leur utilisation | |
US6764996B1 (en) | 9a-azalides with antibacterial activity | |
AU2002300839B2 (en) | Novel aromatic amides, preparation method and application as medicines | |
JPH07196607A (ja) | アニソマイシン誘導体およびそれを含有する抗癌剤、抗真菌剤、および抗原虫剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |